Tamsulosin Hydrochloride Capsule
Product Images NDC 0615-8055

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 0615-8055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 1

FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 2

FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 3

Tamsulosin HCl Caps Aurobindo For Rising 3
The text is showing a figure (Figure 2A) that represents the mean change in Total AUA Symptom Score (ranging from 0-35) for Study 1. The figure compares the treatment with a drug called 0.08mg_A and a placebo, over a period of up to 13 weeks. The number of participants (n) at each time point is also shown in the figure. No further information is available.*
FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 4

Tamsulosin HCl Caps Aurobindo For Rising 4
This is a graph showing the mean change from baseline in Total AUA Symptom Score for different treatments in Study 2. The treatments include 0.4mg and 0.08mg LNt as well as placebo. The graph spans for 13 weeks, and the data has been collected using LOCF method.*
FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 5

Tamsulosin HCl Caps Aurobindo For Rising 5
Figure 3A shows the mean increase in peak urine flow rate (in L/sec) in Study 1. The graph depicts the treatment groups receiving 0.08 mg and 0.4 mg, as well as the placebo group, and the mean change in mL/sec over the duration of treatment in weeks. The number of participants in each group is also shown.*
FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 6

Tamsulosin HCl Caps Aurobindo For Rising 6
This is a figure from Study 2 that shows the mean increase in peak urine flow rate measured in mL/Sec. The x-axis represents the duration of treatment in weeks, and the y-axis shows the increase in peak urine flow rate. The figure is labeled as "Figure 3B" and is divided into 20 treatment groups. However, without the actual figure or additional context, it is difficult to provide a more detailed description.*
FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 7

Tamsulosin HCl Caps Aurobindo For Rising 7
This is a label for Tamsulosin Caps USP 0.4 mg, LOT 8055- with 30 tablets. The label provides information about the manufacturer, the drug's dosage, and storage instructions but no information is provided about its indications or side effects.*
FDA Label Image

Tamsulosin HCl Caps Aurobindo For Rising 8

Tamsulosin HCl Caps Aurobindo For Rising 8
This is a label of Tamsulosin hydrochloride capsules USP, 0.4 mg. The medicine was packaged by Vangard in Glasgow, KY, with a lot number of 8055 and expiry date mentioned as AA 21. The quantity of the medicine is 30, and it is only for institutional use. The label also mentions the manufacturer of the medicine as Aurobindo oy and provides a dosage instruction to refer to new.my_omnicare.com.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.